half of the shares offered were already bought by Zambon Pharma: 4.693 M shares that is the the 19.9% of the Savara outstanding shares. Zanbon is an Italian private Co,with 2800 employees and with sales in Europe , Asia, China, South America but not US, then a perfect commercial partner for the non-US markets. They are also involved in Cystic Fibrosis and respiratory diseases.
IMO a merger could be possible as a medium-term target, likely after Molgradex results and Aerovanc results or interim results. I hope a merger for a worldwide, multi billions combined company next year. 20% could be a down payment for future agreements.
Market Data 
Markets 
AI
